iBio Inc (IBIO)

[guay]

Amidst a global pandemic, two biotech companies offer innovative solutions. In this exclusive interview with BioTuesdays, Tom Isett, co-chairman and CEO of iBio (NYSE AMERICAN:IBIO) and Dr. Robert Foster, CEO of Hepion Pharmaceuticals (NASDAQ:HEPA) discuss how their companies are contributing to the global effort. They are joined by infectious disease expert, Dr. Gerald Parker, and liver disease expert, Dr. Stephen Harrison.
https://biotuesdays.com/2020/03/31/amidst-a-global-pandemic-two-biotech-companies-offer-innovative-solutions/

$IBIO - to have it ready !

IBIO-200 is a virus-like particle (VLP) based vaccine for the COVID-19 disease caused by the SARS-CoV-2 strain of coronavirus. VLP based vaccines are known to interact with immune cells differently than soluble antigens and can trigger both humoral and cellular responses.
IBIO-200 has been designed to maximize uptake by antigen presenting cells in order to increase the overall immune response. A SARS-CoV-2 derived antigen is fused to a self-assembling protein partner to generate the VLP. The antigen is displayed in a repetitive structure and geometry, and the particle is decorated with oligomannose molecules so as to resemble the structure of a naturally occurring virus.
VLP based vaccines are known to interact with immune cells differently than soluble antigens and can trigger both humoral and cellular responses. IBIO-200 has been designed to display enhanced vaccine uptake by antigen presenting cells to increase the overall immune response. As evidenced in the electron micrographs shown here, the FastPharming Manufacturing System delivers a tightly controlled particle size. This offers many quality and scale-up advantages given that the uniform antigen display enables better dose definition and higher product yields. Overall, IBIO-200 is a promising vaccine candidate for the COVID-19 disease, given its designed immunostimulatory properties, quality, and fast scalability to tens of millions of doses.
Source: https://www.ibioinc.com/pipeline

#COVID19 #coronavirus #vaccine #IBIO $IBIO IBIO

About iBio
iBio, Inc., is a global leader in plant-based biologics manufacturing. Its FastPharming System™ combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver gram quantities of high-quality monoclonal antibodies, vaccines, bioinks and other proteins. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services via its 130,000 square foot facility in Bryan, Texas. Originally built in 2010 with funding from the U.S. Defense Advanced Research Projects Agency (DARPA), iBio’s FastPharming Facility was part of the “Blue Angel” initiative to establish facilities capable of rapid delivery of medical countermeasures in response to a disease pandemic. iBio CDMO enables innovators to use the FastPharming System for insourced manufacturing with Factory Solutions “design-and-build” services. iBio’s FastGlycaneering Development Service™ includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Additionally, iBio is developing proprietary products which include IBIO-100 for the treatment of fibrotic diseases. For more information, visit https://www.ibioinc.com.

Contact:
Stephen Kilmer
Investor Relations
[phone]
[e-mail]